Perimetrics, Inc., a dental technology company specializing in quantitative diagnostics, announced that the U.S. Food and Drug Administration (FDA) has cleared its InnerView System. This marks the first FDA-approved technology capable of measuring both internal and external mobility in teeth and dental implants.
The system uses proprietary Quantitative Percussion Diagnostics (QPD) to assess internal mobility—a mechanical response linked to cracks, loose restorations, and other early structural changes that can precede tooth or implant failure.
“Until now, clinicians have relied on subjective assessment or surface observation to detect cracks or failing restorations,” said Robert Hayman, CEO and Chairman of Perimetrics.
“This clearance is a milestone for dentistry. Measuring internal mobility provides objective insight into early changes that may lead to failure.”
Backed by over a decade of research, 30 clinical studies, and 78 global patents, InnerView is the first and only FDA-cleared system to quantify internal mobility in teeth, offering dental professionals a new tool for early intervention.
